Respire_final-01
  • CORPORATE
    • Company Overview
    • Company Management
    • Board of Directors
    • Scientific Team Leaders
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • PHARMACEUTICAL CANNABINOIDS
    • Background
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • NEUROMODULATORS
    • Ampakines
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
      • Autism Spectrum Disorder (ASD)
    • GABAkines
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1 (Page 2)
82 posts, 0 comments

08/04/2020 – RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property

August 4, 2020j3ff1
Read More

08/03/2020 – RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer

August 3, 2020j3ff1
Read More

05/06/2020 – RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer

May 6, 2020j3ff1
Read More

RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.

March 4, 2020j3ff1

Glen Rock, N.J., March 4, 2020,/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety of central nervous system disorders (CNS disorders) and cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that on March 2, 2020, the…

Read More

2/12/2020 – RespireRx Pharmaceuticals Inc. Progress and Status Report

February 12, 2020j3ff1
Read More

2/5/2020 – RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications

February 5, 2020j3ff1
Read More

2/3/2020 – RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors

February 3, 2020j3ff1
Read More

9/9/2019 – RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit

September 10, 2019j3ff1
Read More

7/30/2019 – RespireRx Pharmaceuticals Inc. Send Notice Letter to the Board of Directors of Therapix Biosciences Ltd.

July 30, 2019j3ff1
Read More

2/19/2019 – RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea in Australia, New Zealand and Southeast Asia

February 19, 2019j3ff1
Read More

Posts navigation

< 1 2 3 4 5 … 9 >

Neurotransmission

  • Neurotransmission
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.